Company / Accounts Receivable
FATE THERAPEUTICS INC Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$916.0K
FY2025
5-year range
$916.0K / $38.5M
FY2021-FY2025
Trend
-74.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 7 years, ranging from $500,000 in FY2018 to $38M in FY2022.
Based on SEC 10-K filings.
$916,000 in FY2025 with a 5-year CAGR of -30.2%.
Declined from $2M to $916,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -71.2%
- 5-Year CAGR
- -30.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -30.2%, indicating a declining trend.
- In FY2025, accounts receivable decreased 74.1% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $916.0K | -74.1% |
| FY2024 | $3.5M | +93.8% |
| FY2023 | $1.8M | -95.3% |
| FY2022 | $38.5M | +343.5% |
| FY2021 | $8.7M | +57.3% |
| FY2020 | $5.5M | - |
| FY2019 | - | - |
| FY2018 | $500.0K | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026